Regeneron and Biocon Settle Litigation over EYLEA® Biosimilar Yesafili™
By EsqSocial Corporation 29/04/25
On April 15, 2025, Biocon announced it reached a settlement agreement with Regeneron, dismissing CAFC Appeal No. 24-2002 and Case No. 1:22-cv-00061 (N.D.W. Va.) / MDL 1:24-md-03103 (N.D.W. Va.) and allowing the commercialization of EYLEA® (aflibercept) interchangeable biosimilar Yesafili™ (aflibercept-jbvf) in the second half of 2026, or earlier under certain undisclosed circumstances....
By: Venable LLP